Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Olle Melander

Principal investigator

Default user image.

Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody


  • Zherui Wu
  • Ludovic Fournel
  • Nicolas Stadler
  • Jin Liu
  • Agnès Boullier
  • Nadia Hoyeau
  • Jean François Fléjou
  • Véronique Duchatelle
  • Nouzha Djebrani-Oussedik
  • Mikaël Agopiantz
  • Evelyne Ségal-Bendirdjian
  • Anne Gompel
  • Marco Alifano
  • Olle Melander
  • Jean Trédaniel
  • Patricia Forgez

Summary, in English

Overall survival of patients with metastatic non-small cell lung cancer (NSCLC) has significantly improved with platinum-based salt treatments and recently with targeted therapies and immunotherapies. However, treatment failure occurs due to acquired or emerging tumor resistance. We developed a monoclonal antibody against the proform of neurotensin (LF-NTS mAb) that alters the homeostasis of tumors overexpressing NTSR1. Neurotensin is frequently overexpressed along with its high affinity receptor (NTSR1) in tumors from epithelial origins. This ligand/receptor complex contributes to the progression of many tumor types by activation of the cellular effects involved in tumor progression (proliferation, survival, migration, and invasion). We demonstrate that LF-NTS mAb operates on the plasticity of tumor cells overexpressing NTSR1 and lowers their aggressiveness. The mAb enables the restoration of platinum-based therapies responsiveness, while also decreasing metastatic processes. Efficacy dosage with long-term treatment showed no obvious adverse events, while demonstrating improvement in the performance status. Our data suggests that LF-NTS mAb is an ideal candidate to be safely added to the conventional standard of care in order to improve its efficacy.


  • Cardiovascular Research - Hypertension
  • EpiHealth: Epidemiology for Health
  • EXODIAB: Excellence in Diabetes Research in Sweden

Publishing year







Cancer Letters



Document type

Journal article




  • Cancer and Oncology


  • Advanced lung cancer
  • Anti-tumor drug
  • Neurotensin antibody
  • Restoration of platinum salt-based chemotherapy sensitivity
  • Tumor cell plasticity



Research group

  • Cardiovascular Research - Hypertension


  • ISSN: 0304-3835